Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency (Q39024706)

8 September 2017

title

Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency (English)

1 reference

8 September 2017

Ying Xin

1

1 reference

8 September 2017

Xiang-di Shen

2

1 reference

8 September 2017

Long Cheng

3

1 reference

8 September 2017

De-fei Hong

4

1 reference

8 September 2017

Bin Chen

5

1 reference

8 September 2017

publication date

12 February 2014

1 reference

Cancer Chemotherapy and Pharmacology

8 September 2017

published in

1 reference

8 September 2017

volume

73

1 reference

8 September 2017

issue

4

1 reference

8 September 2017

page(s)

711-719

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-014-2397-9

8 September 2017

exact match

0 references

cites work

Advanced pancreatic carcinoma: current treatment and future challenges

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Pancreatic cancer: basic and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Pancreatic cancer: survival, errors and evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Surgery for pancreatic cancer: recent controversies and current practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Treatment for pancreatic cancer: current therapy and continued progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Apoptosis: targets in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Perifosine: update on a novel Akt inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Gli and hedgehog in cancer: tumours, embryos and stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

A paracrine requirement for hedgehog signalling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Hedgehog signalling in cancer formation and maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

The Hedgehog and Wnt signalling pathways in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

The crosstalk of mTOR/S6K1 and Hedgehog pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Pancreatic cancer in 2010: new insights for early intervention and detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Control of stem cells and cancer stem cells by Hedgehog signaling: pharmacologic clues from pathway dissection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2397-9

10.1007/S00280-014-2397-9

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference